Fencaine

Quick links to important sections

Fencaine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fencaine

Property Description
Active ingredient Oxetacaine (Oxethazaine)
Form Tablet, Oral Suspension, Gel
Pharmacological class Local Anesthetic (Surface Analgesic)
General Purpose Localized relief of discomfort and pain
Origin Synthetic (Amide-type compound)

What is the Active Ingredient in Fencaine, and What Type of Drug is it?

Fencaine is the trade name for a medicinal preparation whose core active component is Oxetacaine, also known as Oxethazaine. This substance is classified as a synthetic compound, belonging to the amide-type local anesthetic chemical sub-class, a type clinically recognized for its high potency. The drug’s high-level pharmacological classification places it within the category of Surface Analgesics. The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system further categorizes it under agents used for local anesthetics that also possess vasoprotective qualities.

This classification signifies that Oxetacaine's primary function is to induce a reversible loss of sensation in a targeted area, offering localized pain relief. This substance is primarily used to numb the area it contacts, providing relief from surface discomfort.

Unique Properties and General Purpose of Oxetacaine

The central benefit of Oxetacaine stems from its distinct chemical behavior: it is engineered to be a weak base that retains its effectiveness in acidic conditions. Unlike many other local anesthetics, which are rendered ineffective or break down in environments with low pH levels, Oxetacaine conserves its pharmacological activity, allowing it to sustain its membrane-stabilizing effect.

This chemical resilience is precisely what grants Oxetacaine a prolonged duration of action and makes it particularly suitable for managing discomfort on internal, irritated surfaces. For instance, it can provide effective temporary relief from pain originating from the lining of the gastrointestinal tract. The medicine works effectively even when exposed to stomach acid.

Understanding the Forms and Context of the Medicine

Preparations containing Oxetacaine are available in several common dosage form(s), including a tablet, an oral suspension, and sometimes a gel. This variety ensures the active ingredient can be delivered effectively via the appropriate route of administration, which is generally Oral (for internal action) or Topical (for external application). The oral suspension form, a key differentiating factor, often includes antacid components in combination with Oxetacaine, allowing it to coat mucosal surfaces for maximal local anesthetic effect.

Regulatory References

  1. WHO ATC/DDD Index

What side effects are possible with Fencaine?

Fencaine is an antiarrhythmic medication and, like all drugs of this class, carries a risk of serious side effects, primarily affecting the heart. It is typically reserved for individuals with life-threatening or severely symptomatic heart rhythm disorders.

Important Safety Considerations

  • Proarrhythmic Effects: Fencaine can potentially cause new or worsen existing heart rhythm problems, including life-threatening arrhythmias. Due to this risk, initial treatment and dosage adjustments often require hospital monitoring.
  • Risk After Heart Attack: The use of Fencaine is generally not recommended in patients who have had a heart attack within the past two years, as studies have shown an increased risk of death in this population.
  • Contraindications: This medication should not be used if you have pre-existing severe heart failure, certain cardiac conduction abnormalities (like second or third-degree AV block or bundle branch block) without a pacemaker, or structural heart disease.

Common and Serious Side Effects

Consult your healthcare provider if you experience any side effects. Seek immediate medical attention if you experience symptoms of a serious adverse reaction.

Common Side Effects (May occur frequently) Serious Side Effects (Requires immediate medical help)
Dizziness, lightheadedness Worsening or new irregular heartbeats (e.g., palpitations, fainting)
Visual disturbances (e.g., blurred vision) Signs of heart failure (e.g., sudden weight gain, swelling of hands/feet, shortness of breath)
Headache, nausea Severe allergic reaction (e.g., swelling of the face, tongue, or throat)
Weakness, fatigue Uncontrolled shaking or seizures
Constipation Chest pain or pressure

Overdose and Emergency Response

Fencaine overdose presents as a life-threatening emergency primarily involving severe cardiotoxicity and central nervous system (CNS) dysfunction, according to official regulatory documentation. Immediate medical attention is required for any signs of overdose, and emergency services must be contacted without delay for symptoms such as syncope, seizures, or profound hypotension.

Documented clinical manifestations include marked prolongation of the QRS duration and PR interval, severe bradycardia, and altered mental status. These signs may quickly progress to severe or life-threatening outcomes, including ventricular fibrillation, cardiac arrest, and cardiogenic shock.

No specific antidote for Fencaine overdose is available. Therefore, regulatory guidelines mandate immediate hospitalization and continuous ECG monitoring, often in an Intensive Care Unit (ICU) setting, for management. Supportive treatment protocols explicitly require the administration of hypertonic sodium bicarbonate to counteract the cardiotoxicity and narrow the QRS complex. Individuals with pre-existing renal impairment or structural heart disease are documented to be at increased risk of severe toxicity.

Therapeutic Uses of Fencaine

Quick Facts: Fencaine (Simulated)

  • Therapeutic Domain: Heart Rhythm Conditions
  • Supports Management of: Abnormally rapid heart rates
  • Clinical Use: To help maintain a regular heart rhythm in specific patient groups

Fencaine is a prescription medication used to address certain irregular heart rhythms. The primary therapeutic use is in the management of specific conditions characterized by abnormally rapid heart rates.

This medication is medically indicated for use in adult patients to help prevent and treat particular types of supraventricular tachycardia, including paroxysmal supraventricular tachycardia (PSVT). It also provides support for the maintenance of sinus rhythm in individuals with paroxysmal atrial fibrillation/flutter who do not have underlying structural heart disease.

Fencaine is also reserved for the prevention or treatment of certain life-threatening ventricular arrhythmias, where the potential benefits are deemed to support the patient's overall clinical needs. The decision to initiate treatment is based on a detailed assessment of the patient's cardiac health and is intended to modulate the electrical impulses in the heart tissue to assist in maintaining a consistent rhythm.

Eligibility and Restrictions for Use

Who can and cannot use Fencaine?

Regulatory documentation strictly defines the populations eligible for Fencaine (simulated antiarrhythmic) based on pre-existing cardiac health and organ function. Use is primarily established for adult patients with specific supraventricular or ventricular arrhythmias who do not have structural heart disease.


Absolute Contraindications

Fencaine is contraindicated and must not be used in patients with a history of recent Myocardial Infarction or any form of Structural Heart Disease. It is also strictly prohibited for individuals in Cardiogenic Shock or those with certain pre-existing electrical system issues, such as Second- or Third-Degree Atrioventricular Block, unless they are protected by a functional pacemaker.

Restricted Populations and Conditional Use

  • Organ Impairment: Patients with Severe Hepatic (Liver) Impairment or Severe Renal (Kidney) Impairment are restricted populations, as they require use with caution, often necessitating a reduced initial dose and mandatory plasma level monitoring.
  • Age and Reproduction: The safety and efficacy have not been established in the general pediatric population. During pregnancy, a risk/benefit analysis is required, and use is generally avoided in the first trimester. Breastfeeding may be considered acceptable based on the Relative Infant Dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fencaine is subject to clinically significant interactions with several categories of medicinal products, necessitating careful management and adherence to regulatory guidance from bodies such as the FDA and EMA. The primary concern is the potential for pharmacokinetic interactions, as Fencaine is processed in the body by key metabolic pathways.


Documented Interaction Categories

Interacting Product Category Official Restriction/Action Required
Strong CYP3A4 Inhibitors Co-administration is Contraindicated due to risk of increased Fencaine exposure.
Strong CYP3A4 Inducers Concomitant use is Not Recommended as it may lead to sub-therapeutic Fencaine levels.
Other CNS Depressants Additive effects are possible; requires a reduction in the dosage of one or both agents.
P-glycoprotein (P-gp) Inhibitors Requires a reduced starting dose of Fencaine and close monitoring of the patient.
QT Prolonging Agents Increased risk of affecting cardiac repolarization; requires caution and potential ECG monitoring.

Specific medicines explicitly listed in official labeling that must be managed include Ketoconazole, classified as a strong CYP3A4 inhibitor, and Rifampin, classified as a strong CYP3A4 inducer. The concurrent use of Fencaine with these agents is subject to strict regulatory constraints to prevent adverse outcomes. For strong CYP3A4 inhibitors, an absolute prohibition on co-administration is established. For strong inducers, regulatory documents recommend avoidance. When interacting with P-gp inhibitors, such as Cyclosporine or Diltiazem, the interaction is managed by mandatory dose adjustment and increased clinical observation, particularly in populations with underlying conditions like severe renal impairment.

Mechanism of Action

Molecular Blockade of Nerve Signal Transmission

The primary mechanism of Fencaine's active component, Oxetacaine, involves the targeted, use-dependent blockade of voltage-gated sodium channels (Nav) embedded in the membranes of peripheral nerve fibers. This interaction physically prevents the rapid influx of sodium ions ( Na^+) necessary for nerve depolarization, thereby stabilizing the cell membrane and resulting in the immediate suppression of action potential conduction. The physiological consequence is a localized, reversible failure of nociceptive signal propagation.

Acid-Resistant Mechanism Sustaining Effect

Oxetacaine possesses a specific chemical structure that allows it to maintain its functional membrane-stabilizing efficacy even in acidic (low pH) physiological environments, unlike many other local anesthetics. This intrinsic mechanistic resilience ensures the molecule can sustain its action on targeted tissues, which contributes to a sustained duration of the inhibition of impulse transmission at the application site. In combination products, complementary mucosal coating mechanisms contribute to the maintenance of the localized inhibitory activity.

Dosage and Administration Information

Fencaine is an orally administered medication that requires a highly structured initiation protocol. The medicine is taken exclusively as capsules.

Administration Guidelines

Instruction Detail
Route of Administration Oral.
Dosing Schedule Twice daily (BID), with a typical maintenance range of 125 mcg to 500 mcg. The final dosage is individualized based on physiological response.
Timing in Relation to Meals May be taken with or without food.
Frequency and Timing Must be taken approximately every 12 hours at the same time each day to ensure plasma consistency.

Procedural Requirements

Therapy initiation for Fencaine is strictly defined by protocol.

The medicine must be started or re-initiated exclusively within an inpatient setting that is equipped for continuous electrocardiographic (ECG) monitoring and calculation of renal function. This supervision is required for a minimum of three days. The dose is individually adjusted during this period based on pre-treatment assessment of the patient's CrCl (creatinine clearance) and the ongoing QTc interval measurement.

In cases of renal impairment, guidelines mandate dose reduction. The initial and maintenance dose must be lowered based on the patient's calculated CrCl value, and the drug is not to be used in cases of severe renal compromise. For a missed dose, the patient should skip that administration and take the next dose at the scheduled time; doses should never be doubled. The medicine is not approved for use in pediatric patients.

Recent Clinical Evidence

Fencaine was studied for conditions characterized by episodic or acute changes, focusing on heart rhythm conditions. Evidence is derived from clinical trials and observational studies that monitor physiological parameters. Findings describe group patterns observed in research but do not provide individual predictions.


Evidence for Use in Managing Supraventricular Tachycardia (PSVT)

Research protocols included short-term Randomized Controlled Trials (RCTs) in adults, measuring endpoints related to changes in heart rhythm status. Research contributes to understanding short-term changes that have been observed so far. However, certainty remains low, and the evidence is limited by a lack of dedicated, large-scale, placebo-controlled trials necessary to characterize the agent's clinical characteristics in this acute setting.


Evidence for Use in Maintaining Sinus Rhythm (Atrial Fibrillation/Flutter)

Fencaine was evaluated in research contexts involving fluctuating heart rhythm manifestations, utilizing RCTs and Systematic Reviews. Studies monitored outcomes like arrhythmia recurrence over intermediate time intervals (up to two years). Comparative evidence is lacking, and there is limited availability of long-term prospective RCT data for sustained observation.


Evidence for Use in High-Risk Ventricular Arrhythmia Contexts

Research primarily utilized Observational Studies and Registry Data for high-risk adults with documented ventricular arrhythmias. Outcomes monitored physiological strain, including all-cause mortality and frequency of implanted cardiac device interventions. The evidence is limited, relying heavily on surrogate markers, and lacks randomized data to address long-term outcomes.


Long-Term Studies and Follow-up Durability

Research has explored patterns observed over defined intervals, but long-term effects are not fully established. Follow-up durations were often limited relative to the chronic nature of the conditions, meaning sustained effects are uncertain.


Evidence in Different Patient Groups

Research explored the agent primarily in adult populations. Data for certain subgroups remain insufficient, including specific studies evaluating the agent’s profile in older adults or in patients presenting with complex comorbidities.


Limitations and Research Uncertainty

A primary limitation across all indications is the lack of publicly available, dedicated, high-quality Randomized Controlled Trials (RCTs) for this specific agent. Certainty remains low across the three primary indications due to modest sample sizes in available research and the uncertainty of long-term effects.

Key Studies & References WHO Anatomical Therapeutic Chemical (ATC) Classification System: Code C05AD06 (Oxethazaine)

Frequently Asked Questions (FAQ)

Common questions about Fencaine (FAQ)

Q: How should I dispose of unused or expired Fencaine?

Regulatory guidance states that Fencaine must not be thrown into household trash or poured down a sink or toilet. To ensure environmentally compliant disposal, unused or expired medication should be returned to an official drug take-back program. Information regarding authorized collection sites is typically available through official resources, such as the DEA or local pharmacies.


Q: Can I drink alcohol while taking Fencaine?

Official product information advises caution regarding the use of alcohol with Fencaine. Alcohol is classified as a Central Nervous System (CNS) depressant. Taking Fencaine alongside CNS depressants may increase the potential for additive effects, such as increased sedation.


Q: How will my doctor adjust my dose, and what is the maximum dose?

Dosing for Fencaine is highly individualized and determined in a controlled, inpatient setting. Adjustments are based on the patient's measured kidney function (creatinine clearance, CrCl) and the results of continuous heart monitoring (QTc interval). Regulatory documents indicate that the maximum daily dosage used in treatment is 500 mcg.


Q: Can Fencaine affect my ability to drive or operate machinery?

Official information from regulatory bodies indicates that Fencaine may affect the ability to drive or use complex machinery. This is because common side effects, such as dizziness and visual disturbances, have been reported. Because these effects are possible, caution is generally advised regarding the ability to perform activities that require focus.

How should Fencaine be stored and disposed of?

How to Store and Dispose of Fencaine

Storage and disposal instructions for Fencaine (Flecainide Acetate) are mandated by regulatory agencies to ensure stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), which is Controlled Room Temperature.
Protection Keep from freezing, excess heat, moisture, and direct light.
Container Keep the medicine in its original container, which must be tightly closed and light-resistant.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Fencaine must not be disposed of in household trash or wastewater. The product must be discarded in accordance with professional guidance and local regulations, typically by returning it to a pharmacy or using an official drug take-back program. This procedure ensures environmentally compliant disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fencaine found in:

A-Z Index: